All In Biotech

NDA 022231 · Mallinckrodt Ireland

Terlivaz

Terlipressin Acetate · Intravenous · Vasopressin Receptor Agonist

NovelPriority reviewOrphan

CDER novel approval, Sep 14, 2022: To improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function

Last checked: Nov 20, 2026Latest source record: Jun 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Sep 14, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

97

26 Phase 3, 5 recruiting

FAERS reports

331

299 serious, 95 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS OR FATAL RESPIRATORY FAILURE TERLIVAZ may cause serious or fatal respiratory failure. Patients with volume overload or with acute-on-chronic liver failure (ACLF) Grade 3 are at increased risk [see References (15) ]. Assess oxygenation saturation (e.g., SpO 2 ) before initiating TERLIVAZ. Do not initiate TERLIVAZ in patients experiencing hypoxia (e.g., SpO 2 <90%) until oxygenation levels improve. Monitor patients for hypoxia using continuous pulse oximetry during treatment and discontinue TERLIVAZ if SpO 2 decreases below 90% [see Dosage and Administration (2.1) , Contraindications (4) , and Warnings and Precautions (5.1) ]. WARNING: SERIOUS OR FATAL RESPIRATORY FAILURE TERLIVAZ may cause serious or fatal respiratory failure. Patients with volume overload or with ACLF Grade 3 are at increased risk. Assess oxygenation saturation (e.g., SpO 2 ) before initiating TERLIVAZ....

What it is approved for

From the label in effect Oct 23, 2026.

TERLIVAZ is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. Limitation of Use Patients with a serum creatinine >5 mg/dL are unlikely to experience benefit. TERLIVAZ is a vasopressin receptor agonist indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. ( 1 ) Limitation of Use Patients with a serum creatinine >5 mg/dL are unlikely to experience benefit. ( 1 )

Mechanism: Terlipressin is a synthetic vasopressin analogue with twice the selectivity for vasopressin V 1 receptors versus V 2 receptors. Terlipressin acts as both a prodrug for lysine-vasopressin, as well as having pharmacologic activity on its own. Terlipressin is thought to increase renal blood flow in patients with hepatorenal syndrome by reducing portal hypertension and blood circulation in portal vessels and increasing effective arterial volume and mean arterial pressure (MAP).

Therapeutic areas: Rare and genetic disease · Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 14, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
  • TERLIVAZ · TERLIPRESSIN ACETATE EQ 0.85MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Terlipressin" as an intervention, any sponsor and status, largest first.

All 97 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective41
  • ascites25
  • diarrhoea23
  • renal impairment20
  • off label use18
  • acute kidney injury17
  • electrocardiogram qt prolonged17
  • multiple organ dysfunction syndrome17
  • product use in unapproved indication17
  • respiratory failure17
  • hepatic encephalopathy16
  • toxicity to various agents16

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20055
20066
20081
20093
20103
20115
20128
20132
201414
201513
20165
20173
20189
201917
202026
202126
202229
202322
202424
202553
202656

Recalls

1 FDA enforcement reports for this application.

  • Feb 6, 2024 · Class II · Ongoing

    cGMP deviations: Temperature excursion due to shipping delay from manufacturer to distributor. Affected distributor has been notified.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 239 on PubMed

Sponsor: Mallinckrodt Ireland

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.